Rafinlar 75mg Capsule 28’s

Rafinlar 75mg Capsule contains the active ingredient dabrafenib, which is used in the treatment of certain types of cancer, including melanoma (a type of skin cancer) and non-small cell lung cancer (NSCLC) that have a mutation in the BRAF gene. Dabrafenib is a kinase inhibitor that specifically targets and inhibits the mutated BRAF protein, which plays a role in promoting cancer cell growth. By blocking this protein, Rafinlar helps slow down or stop the spread of cancer cells. It is often used alone or in combination with other medications to enhance treatment efficacy. Uses:

• Treatment of unresectable or metastatic melanoma with BRAF V600 mutations.
• Used in combination with other medications for BRAF-mutant non-small cell lung cancer (NSCLC).
• Indicated for BRAF-mutated anaplastic thyroid cancer in certain cases.

Side Effects:

• Common side effects: headache, nausea, fatigue, joint pain, rash, and fever.
• Serious side effects: new cancers, bleeding problems, heart issues (such as irregular heartbeat), eye problems (vision changes), and severe skin reactions. Contact a healthcare provider immediately if you experience severe or unusual symptoms.

Key Features:

• Contains dabrafenib, targeting BRAF V600-mutant cancers.
• Works by inhibiting cancer cell growth and proliferation.
• Used alone or with other cancer medications for enhanced efficacy.
• Effective for metastatic melanoma and certain lung cancers with specific mutations.

FAQ:

1. How does Rafinlar 75mg Capsule work in cancer treatment? Rafinlar inhibits the activity of the mutated BRAF protein that drives the growth of cancer cells, slowing down or stopping tumor progression in cancers with this mutation.
2. Who can use Rafinlar? Rafinlar is prescribed for patients with cancers that have a BRAF V600 mutation, such as metastatic melanoma or certain lung cancers, as confirmed through specific genetic testing.
3. What precautions should I take while using Rafinlar? Regular monitoring is required to watch for potential side effects, including new cancers or heart issues. Inform your healthcare provider of any underlying conditions, and avoid sun exposure due to an increased risk of skin reactions.

References:

1. Novartis Pharmaceuticals Corporation. “Rafinlar (dabrafenib) Capsules.” [Accessed on 5 Nov 2024]. Available from: https://en.wikipedia.org/wiki/Dabrafenib
2. European Medicines Agency (EMA). “Dabrafenib Product Information.” [Accessed on 5 Nov 2024]. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2022/fda-dabrafenib-trametinib-braf-solid-tumors